Domenica Lorusso, MD, PhD, on Cervical Cancer: Results From a Trial on Treatment Regimens

2017 ESMO Congress

Domenica Lorusso, MD, PhD, of the National Cancer Institute of Milan, discusses neoadjuvant chemotherapy followed by surgery vs concurrent cisplatin and radiation therapy in patients with stage IB2 to IIB squamous carcinoma of the cervix (Abstract 928O_PR).

Related Videos

Hepatobiliary Cancer

Manuel Hidalgo, MD, PhD, on Biliary Tract Cancer: Results From the PRODIGY 12-ACCORD 18 Trial

Manuel Hidalgo, MD, PhD, of Harvard Medical School, discusses updated phase III findings on relapse-free survival and first overall survival results in adjuvant GEMOX (gemcitabine ...

Head and Neck Cancer

Robert I. Haddad, MD, on Head and Neck Cancer: Results of the CheckMate 141 Trial

Robert I. Haddad, MD, of Dana-Farber Cancer Institute, discusses phase III study results on treatment beyond disease progression with nivolumab in patients with recurrent or metast...

Breast Cancer

Marleen Kok, MD, PhD, on Triple-Negative Breast Cancer: Results From the TONIC Trial

Marleen Kok, MD, PhD, of The Netherlands Cancer Institute, discusses findings from an adaptive phase II noncomparative trial of nivolumab after induction treatment in triple-negati...

Skin Cancer

Jeffrey S. Weber, MD, PhD, on Melanoma: Results of the CheckMate 238 Trial

Jeffrey S. Weber, MD, PhD, of New York University’s Langone Medical Center, discusses study results on adjuvant therapy with nivolumab vs ipilimumab after complete resection of sta...

Gynecologic Cancers

Mansoor Mirza, MD: Ovarian Cancer Treatment and Quality of Life

Mansoor Mirza, MD, of Copenhagen University Hospital, discusses quality of life in patients with recurrent ovarian cancer treated with niraparib (Abstract 930O).

Advertisement

Advertisement



;
Advertisement

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.